Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1497 - Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase 2 ALTA trial


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Dae Ho Lee


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


D.H. Lee1, D. Kim2, D..R. Camidge3, C.J. Langer4, R.M. Huber5, M. Tiseo6, H.L. West7, H.J.M. Groen8, K.L. Reckamp9, M.J. Hochmair10, N.B. Leighl11, K.H. Hansen12, S.N. Gettinger13, L. Paz-Ares14, E.S. Kim15, E.F. Smit16, S. Kim17, Q. Ni18, P. Zhang19, M. Ahn20

Author affiliations

  • 1 Oncology, Asan Medical Center, 138-931 - Seoul/KR
  • 2 Department Of Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR
  • 3 Cancer Center, University of Colorado, Aurora/US
  • 4 Abramson Cancer Center, University of Pennsylvania, 19104 - Philadelphia/US
  • 5 Thoracic Oncology Centre Munich, LMU Klinikum der Universität München, 80336 - Munich/DE
  • 6 Medical Oncology Unit, University Hospital of Parma, 43126 - Parma/IT
  • 7 Oncology, Swedish Cancer Institute, Seattle/US
  • 8 Faculty Of Medical Sciences, University of Groningen and University Medical Center Groningen, 9700 RB - Groningen/NL
  • 9 Comprehensive Cancer Center, City of Hope, 91010 - Duarte/US
  • 10 Department Of Respiratory And Critical Care Medicine, Otto Wagner Spital, 1140 - Vienna/AT
  • 11 Department Of Medical Oncology, Princess Margaret Cancer Centre, M5G 2C1 - Toronto/CA
  • 12 Department Of Oncology, Odense University Hospital, Odense/DK
  • 13 Oncology, Yale Cancer Center, 06520 - New Haven/US
  • 14 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 15 Levine Cancer Institute, Atrium Health, Charlotte/US
  • 16 Pulmonary Diseases Dept, VU University Medical Center, 1066 CX - Amsterdam/NL
  • 17 Medical Oncology, Asan Medical Center, Seoul/KR
  • 18 Biostatistics, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 19 Clinical Research, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge/US
  • 20 Hematology-oncology, Samsung Medical Center, 135-710 - Seoul/KR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1497


We report an analysis of Asian vs non-Asian pts with CRZ-refractory, ALK+ NSCLC from ALTA (NCT02094573).


Pts were stratified by presence of baseline (BL) CNS metastases and best response to prior CRZ and randomized 1:1 to BRG 90 mg qd (arm A) or 180 mg qd with a 7-day lead-in at 90 mg (arm B). Primary endpoint: Investigator-assessed confirmed ORR by RECIST v1.1.


222 pts were randomized; 69 Asian (A/B, n = 39/30), 153 non-Asian (n = 73/80); median age: Asian, 50/56 y; non-Asian, 51/57 y; 85/70% vs 64/66% had BL CNS metastases. As of Sep 2017, median follow-up was 18.4/22.5 mo (A/B) in Asians vs 22.3/24.5 mo in non-Asians. In Asians, median IRC-assessed PFS (mo) was 9.1 (95% CI 5.6–18.2) in A vs 15.6 (9.2–21.2) in B (HR 0.88 [95% CI 0.48–1.62]; P = 0.6808); in non-Asians, PFS (A/B) was 9.9 (9.0–26.3) vs 17.9 (11.6–23.9; HR 0.72 [0.45–1.13]; P = 0.1510) (Table). Of 7/2 (A/B) Asian pts with measurable BL CNS metastases, 3/1 had confirmed intracranial objective responses; in non-Asian pts with measurable BL CNS metastases, IRC-assessed iORR was 53/69% (n = 19/16). In Asians (A vs B) with any BL CNS metastases, IRC-assessed median iPFS (mo) was 15.6 (5.6–18.4) vs 12.8 (7.3–21.1); in non-Asians, 12.8 (7.4–NR) vs 20.7 (11.1–NR). Most common any-grade TRAEs in Asians (≥20%): increased CPK and amylase; in non-Asians, nausea, diarrhea, and increased CPK. Most common grade ≥3 TRAEs (>3%) in Asians: increased CPK; in non-Asians, increased CPK and lipase, hypertension. Early-onset pulmonary AEs occurred in 3 (4%; 1 grade ≥3) Asian (Korean) and 11 (7%; 6 grade ≥3) non-Asian pts. Dose reductions due to AE: 7.7/30.0% in Asian pts; 7.1/28.8% in non-Asian pts; discontinuations due to AE: 7.7/16.7% in Asian pts; 10.0/20.0% in non-Asian pts.Table:


Investigator-AssessedIndependent Review Committee (IRC)–Assessed
Asian (n = 69)Non-Asian (n = 153)Asian (n = 69)Non-Asian (n = 153)
Arm A (n = 39)Arm B (n = 30)Arm A (n = 73)Arm B (n = 80)Arm A (n = 39)Arm B (n = 30)Arm A (n = 73)Arm B (n = 80)
Confirmed ORR, %49 (30–67a)67 (45–84a)44 (31–58a)53 (40–65a)56 (40–72b)67 (47–83b)48 (36–60b)53 (41–64b)
Median DoR in responders,c mo13.7 (5.6–19.4b)13.8 (10.2–14.8b)9.5 (7.4–NRb)16.6 (9.0–24.0b)16.4 (5.6–24.9b)13.9 (7.4–19.4b)24.6 (7.4–NRb)15.7 (12.6–30.2b)
Median PFS,c mo Events, %9.2 (5.6–15.6b) 6915.6 (11.1–15.7b) 609.2 (5.7–11.1b) 6914.7 (10.8–24.0b) 589.1 (5.6–18.2b) 6715.6 (9.2–21.2b) 609.9 (9.0–26.3b) 5317.9 (11.6–23.9b) 45
OSc Median, mo 1-y,c % 2-y,c % NR (18.2–NRb) 77 (60–88b) 56 (37–72b) NR (NR–NRb) 92 (73–98b) 79 (57–91b) 29.5 (14.5–NRb) 67 (54–76b) 53 (41–64b) 34.1 (22.6–NRb) 76 (65–84b) 62 (50–71b) – – – – – – – – – – – –

DoR, duration of response; NR, not reached; ORR, objective response rate; OS, overall survival; PFS, progression-free survival. a97.5% CI (primary endpoint); b95% CI; cKaplan-Meier estimate.


BRG showed comparable efficacy and acceptable safety in Asians and non-Asians in CRZ-refractory ALK+ NSCLC, with nonsignificant, numerically improved PFS at the 180-mg (with lead-in) dose.

Clinical trial identification


Editorial acknowledgement

Peloton Advantage, LLC, an OPEN Health Company, funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Legal entity responsible for the study

ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.


ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.


D.H. Lee: Honoraria (self): AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ChongKunDang, CJ Healthcare, Eli Lilly, Genexine, Janssen, Merck, MSD, Mundipharma, Novartis, Ono, Pfizer, Roche, Samyang Biopharm, ST Cube, Takeda. D. Kim: Research grant / Funding (institution): Alpha Biopharma, Astrazeneca/MedImmune, Hanmi, Janssen, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, Yuhan. D.R. Camidge: Honoraria (self): AstraZeneca, Takeda, Genoptix, G1 Therapeutics [DSMB], Mersana Therapeutics, Roche, Ignyta, Daiichi Sankyo [ILD adjudication committee], Hansoh SRC, Bio-Thera DSMB, Lycera, Revolution Med; Research grant / Funding (self): Takeda. C.J. Langer: Honoraria (self): Bristol-Myers Squibb, Eli Lilly, Roche/Genentech; Advisory / Consultancy: Abbott, ARIAD, AstraZeneca, Bayer/Onyx, Bristol-Myers Squibb, Cancer Support Community, Celgene, Clarient, Clovis Oncology, Eli Lilly, Merck, Roche/Genentech, Takeda; Research grant / Funding (self): Advantagene, ARIAD, Celgene, Clovis Oncology, GlaxoSmithKline, Inovio, Merck, Roche/Genentech, Stemcentrx; Advisory / Consultancy: Amgen, Lilly, Peregrine Pharmaceuticals, Synta. R.M. Huber: Honoraria (self): ARIAD, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Roche; Advisory / Consultancy: Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Eli Lilly, Novartis, Roche; Research grant / Funding (self): Pierre Fabre. M. Tiseo: Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Otsuka, Pfizer, Pierre Fabre, Roche. H.L. West: Advisory / Consultancy: AbbVie, ARIAD, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Merck, PharmaMar, Roche/Genentech, Spectrum, Takeda; Speaker Bureau / Expert testimony: ARIAD, Bristol-Myers Squibb, Roche/Genentech. H.J.M. Groen: Advisory / Consultancy: AbbVie, BMS, Eli Lilly, MSD, Novartis, Pfizer, Roche/Genentech; Research grant / Funding (self): Eli Lilly, Roche. K.L. Reckamp: Advisory / Consultancy: Amgen, ARIAD, Astellas, Takeda, Tesaro; Research grant / Funding (self): Adaptimmune, ARIAD, BMS, Boehringer Ingelheim, AbbVie, Novartis, Pfizer, Roche/Genentech, Xcovery. M.J. Hochmair: Honoraria (self): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche, Takeda; Advisory / Consultancy: Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Roche, Takeda. N.B. Leighl: Travel / Accommodation / Expenses: AstraZeneca, BMS, MSD, Pfizer. K.H. Hansen: Honoraria (self): AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Roche; Advisory / Consultancy: AstraZeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Roche; Travel / Accommodation / Expenses: BMS, Boehringer Ingelheim, MSD, Pfizer, Roche. S.N. Gettinger: Advisory / Consultancy: Alexion Pharmaceuticals, ARIAD, Bristol-Myers Squibb, Pfizer; Research grant / Funding (self): ARIAD, Bristol-Myers Squibb, Incyte, Pfizer, Roche/Genentech. L. Paz-Ares: Honoraria (self), Spouse / Financial dependant: Eli Lilly, MSD, BMS, Roche, PharmaMar, Merck, AstraZeneca, Novartis, Boehringer Ingelheim, Celgene, Servier, Sysmex, Amgen, Incyte, Pfizer, Ipsen, Adacap, Sanofi, Bayer, Blueprint; Officer / Board of Directors: Genomica; Research grant / Funding (institution): MSD, BMS, AstraZeneca, Pfizer. E.S. Kim: Advisory / Consultancy: AstraZeneca, Celgene, Eli Lilly; Honoraria (self): Eli Lilly, AstraZeneca, Celgene. E.F. Smit: Advisory / Consultancy: Eli Lilly; Research grant / Funding (self): AstraZeneca, Bayer, Boehringer Ingelheim, Roche/Genentech. Q. Ni: Full / Part-time employment: Takeda. P. Zhang: Full / Part-time employment: Takeda. M. Ahn: Honoraria (self): AstraZeneca, Boehringer Ingelheim, Lilly, MSD; Advisory / Consultancy: AstraZeneca, Boehringer Ingelheim, Lilly, MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.